Dienogest: an oral progestogen for the treatment of endometriosis

Alfred O. Mueck
In: Expert Review of Obstetrics & Gynecology · 2010 · vol. 6(1) , pp. 5–15 · doi:10.1586/eog.10.71 · W2100042209
article OA: closed CC0 ⤵ 16 in-corpus citations
View on OpenAlex View at publisher

Abstract

Dienogest is a progestogen that combines the pharmacological properties of 19-norprogestins and progesterone derivatives. Dienogest has a potent effect on endometrial tissue, producing antiproliferative effects on endometriotic cells, as well as anti-inflammatory and antiangiogenic actions. Dienogest has been systematically investigated for the treatment of endometriosis through comprehensive study programs in Europe and Japan. Clinical experience of dienogest at 2 mg daily orally demonstrates that it significantly reduces endometriotic lesions and provides effective pain relief comparable to the current efficacy standard, combined with a favorable safety and tolerability profile that allows long-term use. Study data over 15 months show sustained pain relief and low incidences of treatment-related adverse events. As with other progestogens, spotting or breakthrough bleeds are common, but usually lessen during long-term treatment. Dienogest does not produce antiestrogenic side effects, such as bone mass loss. This article reviews the evidence for the use of dienogest in endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (62)

Cited by (16)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-06-13T06:42:57.164913+00:00
License: CC0 · commercial use OK